Market Overview

UPDATE: Northland Downgrades ResMed

Related RMD
Qualcomm Announces New Connected Health Collaborations at Connect 2014
UPDATE: ResMed Receives Permanent Injunction Against APEX In Germany, Continues Enforcement Of Patents in Europe

In a note released Tuesday morning, Northland Securities downgraded ResMed (NYSE: RMD) from Market perform to Underperform and maintained its $40 price target.

In the note, Northland analyst cited "numerous forces" in the CPAP space that will squeeze margins and the top-line overtime. Furthermore, the analysts noted that ResMed's model is "highly sensitive" to operating margins and believe that consensus estimates are "unrealistic."

Shares of ResMed are down a little over one percent at $49.44 in Tuesday's trading.

Latest Ratings for RMD

Aug 2014JefferiesMaintainsHold
Jul 2014Deutsche BankDowngradesBuyHold
Jun 2014JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: Northland SecuritiesDowngrades Price Target Analyst Ratings


Related Articles (RMD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters